GE Healthcare and Osprey Medical (ASX:OSP) have announced a new alliance under which GE Healthcare will exclusively distribute Osprey’s product portfolio in Europe, Russia, Middle East, Africa, Central Asia and Turkey.
Osprey’s DyeVert contrast minimisation devices, complemented by GE Healthcare's range of iodinated x-ray contrast media, will provide healthcare professionals a technology platform to help address the rising problem of Acute Kidney Injury (AKI) following interventional coronary angiograms in patients with Chronic Kidney Disease (CKD).
AKI is sudden damage to the kidneys that causes them to not work properly. It can range from minor loss of kidney function to complete kidney failure.
Patients with impaired kidneys are at a significantly increased risk for negative outcomes and for longer hospital stays.
Under the four-year agreement, GE Healthcare will commercialise Osprey’s DyeVert portfolio that reduces the amount of contrast that reaches the kidney (40 per cent average reduction).
Osprey said its technology is the only FDA cleared medical device indicated for reducing patient contrast exposure. The DyeVert portfolio allows healthcare providers to monitor cumulative dye dose specific to each patient’s kidney function determined prior to the procedure.